Company Overview
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Recent Developments
- Dec 2025 Revenue of $893.00K (+1075.0% YoY); net profit $-68.99M.
- Trailing 12 Months Year-on-year growth — revenue -32.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -32.10% |
Stock Price Performance
| 1 Year: | -16.03% |
| 6 Months: | -16.74% |
| 3 Months: | +16.37% |
| 1 Month: | +21.34% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)68.43 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 39.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PROK ProKidney Corp. PHARMA | 1.99 | -3.62 | $415.76M | 0.00% | -54.13% | -58.96% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 230.00K | 221.00K | 217.00K | 225.00K | 226.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | 41.62M | 39.93M | 38.76M | 45.60M | 45.16M |
| Operating Income | -143 | -17.08M | -66.46M | -20.74M | -35.57M | -40.88M | -39.82M | -46.62M | -40.08M | -43.06M | -48.97M | -41.39M | -39.71M | -38.54M | -45.37M | -44.93M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | -35.76M | -34.65M | -33.61M | -40.60M | -40.95M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | 0 | 1.00K | 2.00K | 1.00K | 15.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | -37.36M | -36.12M | -35.28M | -42.44M | -42.62M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | 591.00K | 848.00K | 560.00K | -1.58M | 0 |
| Net Income | -143 | -252.49K | -3.98M | -2.27M | -29.93M | -9.66M | -9.12M | -10.98M | -9.49M | -12.51M | -17.91M | -16.73M | -16.55M | -16.47M | -19.23M | -20.04M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | -0.13 | -0.13 | -0.12 | - | -0.14 |
| R&D Expense | - | 14.74M | 28.49M | 11.56M | 21.13M | 25.62M | 26.36M | 32.20M | 27.23M | 29.40M | 31.25M | 27.26M | 25.88M | 26.82M | - | 33.84M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 0 | 76.00K | 893.00K |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 153.01M | 151.52M | 183.75M | 165.90M |
| Operating Income | -27.02M | -55.11M | -153.01M | -151.52M | -183.68M | -165.01M |
| EBITDA | - | - | -143.99M | -125.59M | -158.49M | -144.62M |
| Interest Expense | - | - | 215.00K | 12.00K | 9.00K | 4.00K |
| Pretax Income | - | - | -147.24M | -129.45M | -163.93M | -151.20M |
| Tax Provision | - | - | 896.00K | 6.00M | -598.00K | 414.00K |
| Net Income | - | -55.15M | -108.03M | -35.47M | -61.19M | -68.99M |
| Diluted EPS | - | - | -0.23 | -0.57 | -0.62 | -0.52 |
| R&D Expense | 21.04M | 46.26M | 82.07M | 106.71M | 127.67M | 114.12M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Feb 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | 518.00M | 420.55M | 441.07M | 335.57M |
| Current Assets | - | - | - | - | 504.72M | 374.15M | 395.88M | 280.68M |
| Cash & Equivalents | - | - | - | - | 490.25M | 60.65M | 99.12M | 108.54M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | 0 | 1.38M | 2.45M | 1.13M |
| Total Liabilities | - | - | - | - | 13.06M | 29.22M | 39.44M | 34.78M |
| Current Liabilities | - | - | - | - | 10.87M | 25.04M | 36.22M | 30.74M |
| Long Term Debt | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | 2.40M | 4.41M | 3.24M | 4.04M |
| Total Equity | 15.88M | 9.86M | 0 | - | -1.10B | -1.10B | -994.95M | -1.01B |
| Shares Outstanding | - | - | - | - | 61.54M | 59.88M | 128.05M | 141.81M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -25.18M | - | -77.09M | -90.07M | -126.35M | -120.12M |
| Investing Cash Flow | -5.46M | - | -1.74M | -329.98M | 20.41M | 103.97M |
| Financing Cash Flow | 19.99M | - | 548.52M | -9.55M | 144.41M | 25.57M |
| Capital Expenditure | -5.46M | - | -1.85M | -34.20M | -29.51M | -15.20M |
| Free Cash Flow | -30.64M | - | -78.94M | -124.27M | -155.86M | -135.31M |
| Net Change in Cash | - | - | 469.69M | -429.60M | 38.47M | 9.42M |
| Share Buybacks | - | 0 | 0 | 9.50M | 0 | 0 |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | -241,678.9% | -18,477.8% |
| Net Margin % | - | - | - | - | -80,507.9% | -7,725.2% |
| ROE % | - | - | 9.9% | 3.2% | 6.1% | 6.8% |
| ROCE % | - | - | -30.2% | -38.3% | -45.4% | -54.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Montanova Capital LLC | 5.91% | 12.34M | $23.57M |
| 2 | Morgan Stanley | 4.72% | 9.85M | $18.82M |
| 3 | Blackrock Inc. | 2.49% | 5.20M | $9.93M |
| 4 | Geode Capital Management, LLC | 1.14% | 2.39M | $4.57M |
| 5 | Bleichroeder LP | 0.96% | 2.00M | $3.82M |
| 6 | Hennion & Walsh Asset Management, Inc. | 0.88% | 1.85M | $3.53M |
| 7 | Artia Global Partners LP | 0.86% | 1.81M | $3.45M |
| 8 | Vanguard Capital Management LLC | 0.56% | 1.18M | $2.24M |
| 9 | Renaissance Technologies, LLC | 0.53% | 1.10M | $2.10M |
| 10 | Millennium Management Llc | 0.50% | 1.05M | $2.01M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PROK
ProKidney (NASDAQ:PROK) Stock Price Up 7.6% - Should You Buy? - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQT1I5MkhETndFR1RNeTlLLXlHT2pOMWNGSk1zTU9pY2VKb21ZTFlzS0VuUFY5bW01LUs1N3Q1LTAxampFV2d2eDBLeEgtcUlCMExWTmN2ZVBrLU94YUo5N0J6eXFwZDluYXh1M1Bzdjg1cDRKTHpYZHo1RDcxeHpjalZETWdwVEp3QVIzT3…
ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxOODVNZ193UUtBSXVMVUxZN3RSbGNHYXdUeXg4dUtVcU5ZTWZ6RmROeEthVjlqbjNMRVM1akk1WkxPREd5czZEWU5qTnd1bXZjWTJHMzN4SVdrSUFGdlRoX1ZBNkEwbFAweGppTW5OVE8xNXRQSU9ibjBBc25vU3pHeVpVcGRKUG84OGE5Zm…
$PROK stock is up 7% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQWGtveDF6aDNBTzdHMFJnRUN5bTBxNGVWaXcxM2ZZQ0pXVVE2ZVJGajhxcE50UFl2Q24xcE5sNUktSWluc1RXSTFvUlhVZmNPT182TS04aDZtM2d0bWdJTHFpWUs0MmwxWjNXSHRqdnViSFY1X01vUGlJQVVCOGs3UU9ONzJGRnZOM1hkaU…
PROK Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9aQUVkMnczaWdPRUhWTm55NW9FMjdOOUVoVEVkMVlOVnRVUDBEVl9tSUt4Z2dPOEhGd0p3NmxLa3lmalpLWmNqdW9CbXJVemJiamFoempvNzNNek5TVDZRclAzVkZaM2pDeHhxeWRqRkkyRF9RZFRLc293?oc=5" target="_blank">PRO…
3 Promising Penny Stocks With Market Caps Larger Than $200M - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxOZVYyNXB3OEE0LVRNdkVKenh3djdqTFpEVUJ2aW1RS3JBRTZLcFZiUkpkMC1yTk9DaFRIaUpGYWlfNktyN2JMSVJjTm5IRjFibkVHbDh4Mm1rcmczOWpqVmRoUV9tQVUtNWZtdVpNSVh4VEphSm13V0VyOURkcHI4dlhGRFRyejA3cERteD…
ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade) (PROK) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPUTZTemxtclRhVDE4WTVxT1p1cHVQX2Y3cGFzZTRPUlFvSFdBOUc3bXNHTWUtVk1MY2VZTW1heGdEWGJwVFN6T1ozenFQeUotNFBsY1lvRml4bEt0X19LYU9ZLVRvRUYzZkQyU0NtbGtIWE90OHNXU2MxYlNiQlBMT1ZLRjNET0t4aWVzQ0…
PROK — Frequently Asked Questions
What is the current share price of ProKidney Corp. (PROK)?
As of 2026-09-19 21:16 PDT, ProKidney Corp. (PROK) trades at $1.99 on NasdaqCM. Its 52-week range is $1.33 to $3.30.
What is the market capitalisation of PROK?
ProKidney Corp. (PROK) has a market capitalisation of $415.76M on NasdaqCM.
What is the P/E ratio of PROK?
PROK trades at a trailing price-to-earnings (P/E) ratio of -3.62. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -0.44.
What is the return on equity (ROE) of PROK?
PROK has a return on equity (ROE) of -58.96%. Its return on capital employed (ROCE) is -54.13%.
Is PROK a good stock to buy?
This page provides a data-driven analysis of ProKidney Corp. (PROK), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.